On the public citation graph

Standard or High Dose Chemoradiotherapy, with or Without the Protease Inhibitor Nelfinavir, for the Treatment of Locally Advanced Pancreatic Cancer: Efficacy, Safety and Health-Related Quality of Life Outcomes from the Multi-Centre Two Stage Phase 1/Randomised Phase 2 SCALOP-2 Study

https://doi.org/10.2139/ssrn.4706360
0 signed · 42 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2016.4324openalex-extracted
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
inferredcites →https://doi.org/10.1002/cncr.32756openalex-extracted
Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta‐analysis
inferredcites →https://doi.org/10.1016/j.clon.2018.02.067openalex-extracted
Stomach Dose–Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer
inferredcites →https://doi.org/10.1016/j.eclinm.2019.10.013openalex-extracted
Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial)
inferredcites →https://doi.org/10.1016/j.ijrobp.2006.12.053openalex-extracted
Full-Dose Gemcitabine and Concurrent Radiotherapy for Unresectable Pancreatic Cancer
inferredcites →https://doi.org/10.1016/j.ijrobp.2012.02.051openalex-extracted
A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic Cancer
inferredcites →https://doi.org/10.1016/j.ijrobp.2012.09.035openalex-extracted
Duodenal Toxicity After Fractionated Chemoradiation for Unresectable Pancreatic Cancer
inferredcites →https://doi.org/10.1016/j.ijrobp.2015.08.026openalex-extracted
Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer
inferredcites →https://doi.org/10.1016/j.ijrobp.2015.11.026openalex-extracted
Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer
inferredcites →https://doi.org/10.1016/j.ijrobp.2015.12.003openalex-extracted
Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation
inferredcites →https://doi.org/10.1016/j.prro.2013.01.005openalex-extracted
Radiation dose responses for chemoradiation therapy of pancreatic cancer: An analysis of compiled clinical data using biophysical models
inferredcites →https://doi.org/10.1016/j.radonc.2009.04.015openalex-extracted
Dose escalation with proton or photon radiation treatment for pancreatic cancer
inferredcites →https://doi.org/10.1016/j.radonc.2016.03.021openalex-extracted
ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer
inferredcites →https://doi.org/10.1016/j.radonc.2016.03.024openalex-extracted
The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells
inferredcites →https://doi.org/10.1016/j.radonc.2018.11.002openalex-extracted
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma
inferredcites →https://doi.org/10.1016/s0140-6736(10)62307-0openalex-extracted
Pancreatic cancer
inferredcites →https://doi.org/10.1016/s0959-8049(99)00047-7openalex-extracted
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer
inferredcites →https://doi.org/10.1016/s1470-2045(16)00172-8openalex-extracted
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
inferredcites →https://doi.org/10.1016/s2468-1253(19)30327-9openalex-extracted
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
inferredcites →https://doi.org/10.1038/bjc.2017.95openalex-extracted
Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer
inferredcites →https://doi.org/10.1093/annonc/mdn281openalex-extracted
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
inferredcites →https://doi.org/10.1093/annonc/mdv295openalex-extracted
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
inferredcites →https://doi.org/10.1093/jnci/80.10.751openalex-extracted
Treatment of Locally Unresectable Carcinoma of the Pancreas: Comparison of Combined-Modality Therapy (Chemotheraphy Plus Radiotherapy) to Chemotheraphy Alone1
inferredcites →https://doi.org/10.1093/jnci/85.5.365openalex-extracted
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
inferredcites →https://doi.org/10.1136/bmj.c332openalex-extracted
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
inferredcites →https://doi.org/10.1158/0008-5472.can-06-1239openalex-extracted
Nelfinavir Down-regulates Hypoxia-Inducible Factor 1α and VEGF Expression and Increases Tumor Oxygenation: Implications for Radiotherapy
inferredcites →https://doi.org/10.1158/1078-0432.ccr-18-2466openalex-extracted
Clinical Development of Novel Drug–Radiotherapy Combinations
inferredcites →https://doi.org/10.1186/1748-717x-7-156openalex-extracted
Radiation dose ≥54 Gy and CA 19–9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation
inferredcites →https://doi.org/10.1186/s12885-019-5307-zopenalex-extracted
Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)
inferredcites →https://doi.org/10.1186/s13014-022-02076-5openalex-extracted
Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review
inferredcites →https://doi.org/10.1186/s13046-018-0904-2openalex-extracted
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells
inferredcites →https://doi.org/10.1200/jco.1985.3.3.373openalex-extracted
Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study.
inferredcites →https://doi.org/10.1200/jco.2006.07.5663openalex-extracted
Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies
inferredcites →https://doi.org/10.1200/jco.2007.15.2355openalex-extracted
Phase I Trial of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir and Chemoradiation for Locally Advanced Pancreatic Cancer
inferredcites →https://doi.org/10.1200/jco.2008.17.7188openalex-extracted
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
inferredcites →https://doi.org/10.1200/jco.2011.34.8904openalex-extracted
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
inferredcites →https://doi.org/10.1200/jco.2016.67.5561openalex-extracted
Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
inferredcites →https://doi.org/10.1371/journal.pmed.1000267openalex-extracted
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
inferredcites →https://doi.org/10.3109/07853890109002087openalex-extracted
EQ-SD: a measure of health status from the EuroQol Group
inferredcites →https://doi.org/10.3322/caac.21660openalex-extracted
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
inferredcites →https://doi.org/10.3390/cancers13174326openalex-extracted
Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis
inferredcites →https://doi.org/10.4103/0971-5916.180201openalex-extracted
Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.